Boston Scientific Corp
$
35.89
0.96 (2.75%)
| Volume: | 13,695,812 | Avg Vol (1m): | 7,712,742 |
| Market Cap $: | 49.72 Bil | Enterprise Value $: | 56.63 Bil |
| P/E (TTM): | 30.04 | P/B: | 5.68 |
| Earnings Power Value | 14.14 |
| Net Current Asset Value | -5.98 |
| Tangible Book | -4.02 |
| Projected FCF | 9.9 |
| Median P/S Value | 15.91 |
| Graham Number | 0 |
| Peter Lynch Value | 0 |
| DCF (FCF Based) | 0 |
| DCF (Earnings Based) | 0 |
YTD (-%)
Add to portfolio
Email alerts
Stock PDF
RSS
Website
Filings
Download Excel
Batch Download
Manual of Stocks™ Web
Manual of Stocks™
Manual of Stocks™ Web
Manual of Stocks™
Financial Strength : 5/10
| Current | vs industry | vs history | |
|---|---|---|---|
| Cash-to-Debt | 0.02 | ||
| Equity-to-Asset | 0.42 | ||
| Debt-to-Equity | 0.81 | ||
| Debt-to-EBITDA | 3.12 | ||
| Interest Coverage | 6.92 | ||
| Piotroski F-Score | 6 |
0
1
2
3
4
5
6
7
8
9
| |
| Altman Z-Score | 2.57 |
DISTRESS
GREY
SAFE
| |
| Beneish M-Score | -2.12 |
Not Manipulator
Manipulator
| |
| WACC vs ROIC % |
ROIC 14.07%
WACC 6.91%
| ||
Profitability & Growth : 8/10
| Current | vs industry | vs history | |
|---|---|---|---|
| Operating Margin % | 16.91 | ||
| Net Margin % | 17.01 | ||
| ROE % | 21.53 | ||
| ROA % | 8.42 | ||
| ROC (Joel Greenblatt) % | 77.90 | ||
| 3-Year Total Revenue Growth Rate | 9.50 | ||
| 3-Year Total EBITDA Growth Rate | 85.10 |
» BSX's 30-Y Financials
Financials (Next Earnings Date: 2019-04-24)
Guru Trades Click for details
Guru Trades in
SEC Filings
Gurus Latest Trades with NYSE:BSX
» Interactive Chart
Peter Lynch Chart
Business Description
| Industry | Medical Devices » Medical Devices   NAICS : 339112   SIC : 3841 |
| Compare | NAS:ISRG NYSE:EW NYSE:ZBH NAS:ALGN LSE:SN. NYSE:SYK NAS:ABMD NYSE:TFX XSWX:SOON NYSE:VAR SZSE:300003 OCSE:WDH XPAR:DIM ASX:COH LSE:CTEC NZSE:FPH NYSE:GMED OCSE:AMBU B NAS:IART OCSE:GN |
| Traded in other countries | |
| Address | 300 Boston Scientific Way, Marlborough, MA, USA, 01752-1234 |
| Boston Scientific produces less-invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract tests, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales. | |
Ratios
| Current | vs industry | vs history | |
|---|---|---|---|
| PE Ratio (TTM) | 30.04 | ||
| Forward PE Ratio | 21.98 | N/A | |
| PE Ratio without NRI | 30.04 | ||
| Price-to-Owner-Earnings | 25.03 | ||
| PB Ratio | 5.68 | ||
| PS Ratio | 5.10 | ||
| Price-to-Operating-Cash-Flow | 161.81 | ||
| EV-to-EBIT | 34.07 | ||
| EV-to-EBITDA | 25.06 | ||
| EV-to-Revenue | 5.77 | ||
| PEG Ratio | 0.78 | ||
| Current Ratio | 0.76 | ||
| Quick Ratio | 0.54 | ||
| Days Inventory | 141.29 | ||
| Days Sales Outstanding | 59.75 | ||
| Days Payable | 44.20 |
Dividend & Buy Back
| Current | vs industry | vs history | |
|---|---|---|---|
| 3-Year Share Buyback Rate | -0.90 |
Valuation & Return
| Current | vs industry | vs history | |
|---|---|---|---|
| Price-to-Projected-FCF | 3.61 | ||
| Price-to-Median-PS-Value | 2.25 | ||
| Earnings Yield (Joel Greenblatt) % | 2.92 | ||
| Forward Rate of Return (Yacktman) % | -15.68 |
More Statistics
| Revenue (TTM) (Mil) $ | 9,823 |
| EPS (TTM) $ | 1.19 |
| Beta | 0.82 |
| Volatility % | 18.73 |
| 52-Week Range $ | 27.91 - 41 |
| Shares Outstanding (Mil) | 1,390.5 |
Analyst Estimate
Piotroski F-Score Details
| Piotroski F-Score | 6 |
| Positive ROA | Y |
| Positive CFROA | Y |
| Higher ROA yoy | Y |
| CFROA > ROA | N |
| Lower Leverage yoy | N |
| Higher Current Ratio yoy | Y |
| Less Shares Outstanding yoy | N |
| Higher Gross Margin yoy | Y |
| Higher Asset Turnover yoy | Y |